Abstract
The improvement of techniques for extracorporeal circulation and particularly the use of more compact and biocompatible circuits allow working in complete safety with lower levels of anticoagulation. From this perspective it is useful to set new objectives in terms of effectiveness for the anticoagulation during cardiopulmonary bypass. Due to individual susceptibility towards heparin, it is useful to adopt a strategy based on personalized prescriptions. This therapeutic objective is easy to achieve by means of a series of simple tests accomplished in the operative theater and allowing to establish the individual dose-response curve for unfractionated heparin.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
